Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas

2006 ◽  
Vol 66 (4) ◽  
pp. 1044-1050 ◽  
Author(s):  
Allen M. Chen ◽  
M. Kara Bucci ◽  
Jeanne M. Quivey ◽  
Joaquin Garcia ◽  
David W. Eisele ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Salivary Gland ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Salivary Gland Carcinomas

Long-term outcomes in children with glioblastoma

2010 ◽  
Vol 6 (2) ◽  
pp. 145-149 ◽  
Author(s):  
Kyung Sun Song ◽  
Ji Hoon Phi ◽  
Byung-Kyu Cho ◽  
Kyu-Chang Wang ◽  
Ji Yeoun Lee ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Progression Free Survival ◽  
Radical Resection ◽  
Tumor Location ◽  
Recurrent Glioblastoma ◽  
Subtotal Resection ◽  
Long Term Outcomes ◽  
Term Outcome ◽  
Long Term Outcome

Object Glioblastoma is the most common primary malignant brain tumor; however, glioblastoma in children is less common than in adults, and little is known about its clinical outcome in children. The authors evaluated the long-term outcome of glioblastoma in children. Methods Twenty-seven children were confirmed to have harbored a glioblastoma between 1985 and 2007. The clinical features and treatment outcomes were reviewed retrospectively. All patients underwent resection; complete resection was performed in 12 patients (44%), subtotal resection in 12 patients (44%), and biopsy in 3 patients (11%). Twenty-four patients (89%) had radiation therapy, and 14 (52%) patients received chemotherapy plus radiation therapy. Among the latter, 5 patients had radiation therapy concurrent with temozolomide chemotherapy. Four patients with small-size recurrent glioblastoma received stereotactic radiosurgery. Results The median overall survival (OS) was 43 months, and the median progression-free survival was 12 months. The OS rate was 67% at 1 year, 52% at 2 years, and 40% at 5 years. The median OS was significantly associated with tumor location (52 months for superficially located tumors vs 7 months for deeply located tumors; p = 0.017) and extent of removal (106 months for completely resected tumors vs 11 months for incompletely resected tumors; p < 0.0001). Conclusions The prognosis of glioblastoma is better in children than in adults. Radical resection followed by concurrent chemoradiation therapy may be the initial treatment of choice.

scholarly journals Long-term Outcome of Involved Node Radiation Therapy for Early Stage Hodgkin Lymphoma

2018 ◽  
Vol 102 (3) ◽  
pp. S123
Author(s):  
K. Nielsen ◽  
M.V. Maraldo ◽  
M.C. Aznar ◽  
P.M. Petersen ◽  
I. Vogelius ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin Lymphoma ◽  
Early Stage ◽  
Term Outcome ◽  
Long Term Outcome

Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome

2020 ◽  
Vol 150 ◽  
pp. 236-244
Author(s):  
Karin Nielsen ◽  
Maja Vestmoe Maraldo ◽  
Anne Kiil Berthelsen ◽  
Annika Loft ◽  
Peter de Nully Brown ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin Lymphoma ◽  
Early Stage ◽  
Combined Modality Treatment ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Combined Modality

Long-term outcome of patients with hepatocellular carcinoma treated with hypofractionated stereotactic radiation therapy as a bridge to liver transplantation.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 368-368
Author(s):  
Alan W. Katz ◽  
Douglas P Rosenzweig
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Complete Response ◽  
Pathological Examination ◽  
Invasive Treatment ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Stereotactic Radiation ◽  
Bridge Therapy

368 Background: Stereotactic hypofractionated radiation therapy (SHORT) is a safe, non-invasive, treatment modality for patients with hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the long-term outcome of patients with HCC receiving SHORT as a bridge therapy to LT. Methods: We reviewed 9 consecutive patients who underwent LT between 2008 and 2010 after receiving SHORT as bridge therapy. Radiation therapy was delivered using a 6 MV linear accelerator and an infrared based patient posititiong system. Total dose was 50 Gy in 10 fractions. Doses were prescribed to the 100% isodose line (IDL), with the 80% IDL covering the gross tumor plus a minimum margin of 7 mm. Survival was measured from the date of LT. Results: Median time from completion of SHORT to LT was 5.9 months (range; 0.9-15.7 months). After a median follow up of 48.6 months (range; 17.8-65.3 months) all patients were still alive. No significant surgical complications were seen in any of the patients. 8 patients demonstrated necrosis in the treated tumors, ranging from 8-100%. Only 1 patient did not show any treatment effect on pathological examination. One patient developed recurrent disease in a lymph node and in the transplanted liver, both treated by SHORT with complete response. Conclusions: SHORT is a safe and effective bridging therapy with patients experiencing excellent disease-free and overall survival following LT.

Sign in / Sign up

Export Citation Format

Share Document